$RARE

Ultragenyx (RARE) CFO sells 4,683 shares, retains 80,351 stake

Ultragenyx Pharmaceutical Inc.'s CFO, Howard Horn, sold 4,683 shares of common stock at $20.97 per share in an open-market transaction. Following this sale, Horn directly holds 80,351 shares, which include restricted stock units. This transaction was disclosed in a Form 4 filing and is part of a 10b5-1 plan.

Original reporting
Published Apr 3, 2026, 10:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 3, 2026, 10:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$RARE
Bearish
medium confidence
Mentioned
$RARE
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$RAREBearishLow
01

Why it matters

The insider sale is within planned trading parameters and does not necessarily indicate negative outlook, but warrants monitoring.

02

Market read

Limited immediate impact; primarily relevant for short-term traders and investors monitoring insider activity.

03

What to watch

The sale might be motivated by personal financial needs unrelated to company performance; further analysis needed.

Timing: short-term

Background

Ultragenyx is a biotech company involved in rare disease treatments, with recent insider activity indicating routine portfolio management.

Company-level read

Ticker impact

$RAREBearishMedium confidence
Context

The insider trading activity of Ultragenyx's CFO may reflect personal financial planning rather than company outlook, but it warrants attention due to the company's involvement in life sciences and recent insider activity.

Expected impact

Potential short-term minor decline or sideways movement; long-term impact remains uncertain.

Evidence & confidence

The insider sale, while notable, is within a planned sale framework, reducing the likelihood of negative signaling. The stock's recent sentiment is somewhat bearish, but the sale alone does not confirm a fundamental change.

Market effects

Potential minor impact on biotech and life sciences sector sentiment; broader market effects are minimal.

Limited regional impact; primarily affects investor sentiment in the company's primary markets.

Low; specific to company and sector.

Counterpoint

The insider sale could be a sign of internal concerns about future prospects, warranting a cautious approach.

Key entities

  • Howard Horn

    CFO of Ultragenyx who sold shares.

  • Ultragenyx Pharmaceutical Inc.

    Biotech company specializing in rare diseases.

Related articles

$RAREMed

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights

Ultragenyx Pharmaceutical (NASDAQ:RARE) reaffirmed revenue and 2026 combined R&D and SG&A guidance, expecting flat to down low single digits from 2025, and at least a 15% decline in 2027. In Q2, Crysvita patient starts rose in Latin America and Turkey, and DOJOLVI had about 675 reimbursed patients in North America. FDA PDUFA dates are Aug. 23 for DTX-401 and Sept. 19 for UX-111.

$ACIMed

Albertsons recalls ready-to-eat items in multiple states amid salmonella-linked jalapeño investigation

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.

$CMGMed

Salmonella outbreak from Mexican jalapeños reported in 27 U.S. states

U.S. health authorities are investigating a Salmonella outbreak linked to Mexican jalapeño peppers. The CDC and FDA say 345 people are ill across 27 states, with 36 hospitalizations and no deaths. The supplier, Coast Citrus Distributors, recalled peppers sent to restaurants including Chipotle and QDOBA. Chipotle removed jalapeños from some outlets and shares fell over 8% on Aug. 4.